Almirall’s Ilumetri shown to improve and maintain well-being in plaque psoriasis patients

2024-07-02

临床结果上市批准

Almirall’s Ilumetri shown to improve and maintain well-being in plaque psoriasis patients

Preview

来源: PMLiVE

Almirall has presented positive results for Ilumetri (tildrakizumab) in patients with moderate-to-severe plaque psoriasis at the International Federation of Psoriasis Association Conference 2024 in Sweden.

The POSITIVE clinical study has been evaluating the impact and skin clearance of Ilumetri in 782 adults with moderate-to-severe psoriasis and is the first dermatological study to use the five-item World Health Organization Wellbeing Index, a questionnaire widely used to assess health-related subjective psychological well-being in a variety of chronic diseases.

Affecting around 60 million people globally, psoriasis is characterised by flaky patches of skin, of which nearly 77% of patients reported that it negatively affects their normal daily activities and well-being.

Ilumetri is a humanised monoclonal antibody that works to inhibit the release of proinflammatory cytokines and chemokines without affecting the rest of the immune system.

Interim results showed that Ilumetri demonstrated notable improvements in skin clearance, particularly in sensitive areas such as the scalp, nail and palms/soles, as well as in high burden symptoms, including itch, pain, joint pain and fatigue, with almost six out of ten patients achieving a Psoriasis Area and Severity Index response of one or below at 52 weeks, with no new safety signals observed, which are consistent with previous studies.

Furthermore, as early as 16 weeks, Ilumetri effectively restored the level of well-being of patients with moderate-to-severe plaque psoriasis to that of the general population, highlighting the importance of understanding the psychosocial burden of psoriasis beyond the physical symptoms.

Commenting on the results, Dr Volker Koscielny, chief medical officer, Almirall, said: “These findings represent a significant milestone in our ongoing efforts to address the needs of patients and dermatologists to treat chronic dermatological conditions and help improve the patients’ health and well-being.”

Earlier this year, the company presented preliminary results from the POSITIVE study at the 2024 World Congress of Dermatology in Singapore.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构